BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock (PHGE.U)

PHGE.U was delisted on the 24th of October, 2024.

• Market cap: $4.14M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Employees: 71